Nástroje

iconicon Akciový screener
iconicon Kalendář zisků
iconicon Super investoři

Ostatní

iconicon Návod
IČ: 19940963

5. května 521, 501 01 Turnov
Zásady GDPR
Podmínky služby
Všechna práva vyhrazena @ 2024, Fundamenty.cz
Proudly created by draftspot.net
Ascendis Pharma A/S
Ascendis Pharma A/S
ASND
Valuace
100
Růst
75
Zdraví
75
Cena
$ 228.51
Dnes
-9.21 (-4.28%)
Souhrn
Výkazy
Ukazatele
Profil
Držitelé
Návštěvnost webu
Konkurence
Zprávy společnosti
Kapitalizace
12.0B
Obrat
1B
Zisk
0B
Aktiva
1B
Dluh
1B
ROE
0%
ROA
0%
PE
-60
PS
19
Cena 1R
118-230
⌀ Cena
187.13
Dividenda
0.0(0.0%)
Nadcházející oznámení zisků
Poslední dividenda

Profil

Společnost Ascendis Pharma A/S, biofarmaceutická společnost, se zaměřuje na vývoj léčebných postupů pro nenaplněné lékařské potřeby. Společnost nabízí přípravek SKYTROFA k léčbě pacientů s nedostatkem růstového hormonu (GHD). Dále vyvíjí TransCon růstový hormon (hGH) pro dětské GHD v Japonsku, TransCon hGH pro dospělé s GHD, TransCon parathormon pro dospělé hypoparatyreózu a TransCon CNP pro dětskou achondroplasii. Kromě toho společnost vyvíjí TransCon mýtné jako receptory 7/8 agonista pro intraumorální porod; a TransCon IL-2 ß/g pro systémový porod. Společnost byla založena v roce 2006 a má sídlo v Hellerup v Dánsku.
Sektor
Healthcare
Odvětví
Biotechnology
Počet zaměstnanců
1017
Založení
2015-01-28
Adresa
Tuborg Boulevard 12
CEO
Jan Moller Mikkelsen
Web
ascendispharma.com

Podobné společnosti

IONS
Ionis Pharmaceuticals, Inc.
$ 69.82
- $ 3.73
BBIO
BridgeBio Pharma, Inc.
$ 62.94
+ $ 1.14
RVMD
Revolution Medicines, Inc.
$ 62.37
+ $ 1.36
ROIV
Roivant Sciences Ltd.
$ 20.80
+ $ 0.18
SMMT
Summit Therapeutics Inc.
$ 17.99
- $ 0.20
GH
Guardant Health, Inc.
$ 97.21
+ $ 0.49
MDGL
Madrigal Pharmaceuticals, Inc.
$ 487.29
- $ 1.97

Zahraniční články

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

New InsiGHTS Trial of TransCon® hGH (Lonapegsomatropin) in Turner Syndrome Demonstrated Comparable Efficacy and Safety to Daily Somatropin at Week 52

8:30 17-03-2026

- Annualized height velocity of 9.05 cm/year (LS mean) for TransCon hGH-treated children was similar...

Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND

Bamco Inc. NY Makes New $1.11 Million Investment in Ascendis Pharma A/S $ASND

3:36 17-03-2026

Bamco Inc. NY bought a new stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) during the undefine...

Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND

Ally Bridge Group NY LLC Acquires Shares of 51,080 Ascendis Pharma A/S $ASND

3:30 15-03-2026

Ally Bridge Group NY LLC bought a new position in shares of Ascendis Pharma A/S (NASDAQ: ASND) in th...

Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND

Barometer Capital Management Inc. Buys 2,900 Shares of Ascendis Pharma A/S $ASND

4:02 12-03-2026

Barometer Capital Management Inc. increased its position in Ascendis Pharma A/S (NASDAQ: ASND) by 28...

Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages

Ascendis Pharma A/S (NASDAQ:ASND) Receives Average Rating of “Moderate Buy” from Brokerages

2:10 10-03-2026

Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) has earned a consensus rating of "Moderate Buy"...

Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript

14:42 04-03-2026

Ascendis Pharma A/S (ASND) Presents at TD Cowen 46th Annual Health Care Conference Transcript...

Ascendis Pharma: Yuviwel Approved Despite Legal Challenges

Ascendis Pharma: Yuviwel Approved Despite Legal Challenges

12:05 03-03-2026

Ascendis Pharma secured FDA approval for Yuviwel in achondroplasia, despite ongoing legal challenges...

Ascendis Pharma FY 2025 Results: More Than A Takeover Story

Ascendis Pharma FY 2025 Results: More Than A Takeover Story

7:33 12-02-2026

Ascendis Pharma has transitioned into a revenue-scaled commercial biotech, driven by Yorvipath's rap...

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript

20:24 11-02-2026

Ascendis Pharma A/S (ASND) Q4 2025 Earnings Call Transcript...

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results

16:01 11-02-2026

COPENHAGEN, Denmark, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno...

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026

16:01 04-02-2026

COPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today anno...

HARBOR CAPITAL ADVISORS, INC. Sells 269 Shares of Ascendis Pharma AS (ASND)

HARBOR CAPITAL ADVISORS, INC. Sells 269 Shares of Ascendis Pharma AS (ASND)

13:52 20-01-2026

Summary HARBOR CAPITAL ADVISORS, INC. reduced its stake in Ascendis Pharma AS (ASND) by 1.17%, selli...

Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?

Ascendis Pharma (ASND) Surges 3.0%: Is This an Indication of Further Gains?

7:15 14-01-2026

Ascendis Pharma (ASND) witnessed a jump in share price last session on above-average trading volume....

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

15:46 12-01-2026

Ascendis Pharma A/S (ASND) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript...

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CNP and Growth Hormone in Achondroplasia Transcript

22:34 08-01-2026

Ascendis Pharma A/S (ASND) Discusses Week 52 Topline Results From COACH Trial Evaluating TransCon CN...

Braun Stacey Associates Inc. Makes New $18.68 Million Investment in Ascendis Pharma A/S $ASND

Braun Stacey Associates Inc. Makes New $18.68 Million Investment in Ascendis Pharma A/S $ASND

3:36 02-01-2026

Braun Stacey Associates Inc. purchased a new stake in shares of Ascendis Pharma A/S (NASDAQ: ASND) d...

ARS Investment Partners LLC Decreases Stock Position in Ascendis Pharma A/S $ASND

ARS Investment Partners LLC Decreases Stock Position in Ascendis Pharma A/S $ASND

3:18 25-12-2025

ARS Investment Partners LLC reduced its holdings in shares of Ascendis Pharma A/S (NASDAQ: ASND) by ...

Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Buy” by Analysts

Ascendis Pharma A/S (NASDAQ:ASND) Given Average Recommendation of “Buy” by Analysts

1:28 25-12-2025

Shares of Ascendis Pharma A/S (NASDAQ: ASND - Get Free Report) have been given a consensus rating of...

Ascendis: Q3 Results Validate The TransCon Platform

Ascendis: Q3 Results Validate The TransCon Platform

4:48 05-12-2025

Ascendis Pharma has achieved operational profitability, driven by YORVIPATH's rapid adoption and str...

Ascendis Pharma A/S $ASND Shares Bought by American Century Companies Inc.

Ascendis Pharma A/S $ASND Shares Bought by American Century Companies Inc.

3:05 26-11-2025

American Century Companies Inc. lifted its position in Ascendis Pharma A/S (NASDAQ: ASND) by 14.9% d...

Výsledovka

Rozvaha

Peněžní toky

Akciový screener
Kalendář zisků
Super investoři
Porovnání akcií
preloader